Neurosarcoidosis
Open Access
- 13 May 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To characterize patients with neurosarcoidosis within the University of Utah healthcare system, including demographics, clinical characteristics, treatment, and long-term outcomes. Methods We describe the clinical features and outcomes of patients with neurosarcoidosis within the University of Utah healthcare system (a large referral center for 10% of the continental United States by land mass). Patients were selected who met the following criteria: (1) at least one International Classification of Diseases Clinical Modification, 9th revision code 135 or International Classification of Diseases Clinical Modification, 10th revision code D86* (sarcoidosis) and (2) at least one outpatient visit with a University of Utah clinician in the Neurology Department within the University of Utah electronic health record. Results We identified 56 patients meeting the study criteria. Thirty-five patients (63%) were women, and most patients (84%) were white. Twelve patients (22%) met the criteria for definite neurosarcoidosis, 36 patients (64%) were diagnosed with probable neurosarcoidosis, and 8 patients (14%) were diagnosed with possible neurosarcoidosis. A total of 8 medications were used for the treatment of neurosarcoidosis. Prednisone was the first-line treatment in 51 patients (91%). Infliximab was the most effective therapy, with 87% of patients remaining stable or improving on infliximab. Treatment response for methotrexate and azathioprine was mixed, and mycophenolate mofetil and rituximab were the least effective treatments in this cohort. Conclusions This is a comprehensive characterization of neurosarcoidosis within a single healthcare system at the University of Utah that reports long-term response to treatment and outcomes of patients with neurosarcoidosis. Our results suggest the use of infliximab as a first-line therapy for neurosarcoidosis.Keywords
This publication has 18 references indexed in Scilit:
- Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based StudyLung, 2015
- Overview of neurosarcoidosis: recent advancesZeitschrift für Neurologie, 2014
- The Variable in Common Variable Immunodeficiency: A Disease of Complex PhenotypesThe Journal of Allergy and Clinical Immunology: In Practice, 2013
- The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseasesRheumatology, 2013
- A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st centuryCurrent Opinion in Pulmonary Medicine, 2010
- Presentations and outcomes of neurosarcoidosis: a study of 54 casesQJM: An International Journal of Medicine, 2009
- Neurosarcoidosis: a clinical dilemmaThe Lancet Neurology, 2004
- Racial Differences in Sarcoidosis Incidence: A 5-Year Study in a Health Maintenance OrganizationAmerican Journal of Epidemiology, 1997
- NeurosarcoidosisMedicine, 1990
- Sarcoidosis and Its Neurological ManifestationsArchives of Neurology, 1985